• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重症肌无力的胸腺切除术:近期观察及与既往经验的比较

Thymectomy for myasthenia gravis: recent observations and comparisons with past experience.

作者信息

Mulder D G, Graves M, Herrmann C

机构信息

Department of Cardiothoracic Surgery, University of California, Los Angeles, School of Medicine.

出版信息

Ann Thorac Surg. 1989 Oct;48(4):551-5. doi: 10.1016/s0003-4975(10)66861-0.

DOI:10.1016/s0003-4975(10)66861-0
PMID:2802856
Abstract

To our previous report on the results of thymectomy for myasthenia gravis in 249 patients operated on between 1954 and 1981, we add a current review of 84 patients treated between 1982 and 1987. All patients underwent a median sternotomy, although this was performed after a bilateral submammary skin incision in most of the 57 female patients. There were no operative deaths, but one late death occurred at 5 months. During a mean followup of 3.6 years, 67 patients (80%) benefited from operation with remission achieved in 30 (36%) and improvement noted in 37 (44%). Acetylcholine receptor site antibody was present in 43 patients, of whom 19 (44%) achieved remission in contrast to 9 (27%) of the 33 patients without antibody. Hyperplasia of the excised thymus in 38 patients was associated with remission in 20 (53%) in contrast to remission in 7 (20%) of the 35 patients whose glands were "normal" or atrophic. The best prognosis was found in the 23 patients who had both receptor site antibody and thymic hyperplasia, as remission occurred in 15 of them (65%) in contrast to only 6 (27%) of the 22 patients who had neither factor. Remission rates (remissions per 1,000 patient-months of follow-up) for the present series (84 patients), the previous group (249 patients), and the overall group (333 patients) are 9.95, 6.13, and 6.62, respectively.

摘要

在我们之前关于1954年至1981年间接受胸腺切除术治疗重症肌无力的249例患者结果的报告基础上,我们增加了对1982年至1987年间接受治疗的84例患者的最新回顾。所有患者均接受了正中胸骨切开术,不过在57例女性患者中的大多数,此手术是在双侧乳房下皮肤切口后进行的。无手术死亡,但有1例患者在术后5个月出现晚期死亡。在平均3.6年的随访期间,67例患者(80%)从手术中获益,其中30例(36%)病情缓解,37例(44%)病情改善。43例患者存在乙酰胆碱受体位点抗体,其中19例(44%)病情缓解,而33例无抗体患者中有9例(27%)病情缓解。38例切除的胸腺增生患者中有20例(53%)病情缓解,相比之下,35例胸腺“正常”或萎缩患者中有7例(20%)病情缓解。预后最佳的是23例同时具有受体位点抗体和胸腺增生的患者,其中15例(65%)病情缓解,而22例既无上述因素的患者中只有6例(27%)病情缓解。本系列(84例患者)、之前一组(249例患者)以及总体组(333例患者)的缓解率(每1000患者 - 月随访期内的缓解例数)分别为9.95、6.13和6.62。

相似文献

1
Thymectomy for myasthenia gravis: recent observations and comparisons with past experience.重症肌无力的胸腺切除术:近期观察及与既往经验的比较
Ann Thorac Surg. 1989 Oct;48(4):551-5. doi: 10.1016/s0003-4975(10)66861-0.
2
[Thymic lymphoid hyperplasia of myasthenia gravis patients: correlation with clinical features and efficacy of thymectomy].[重症肌无力患者的胸腺淋巴样增生:与临床特征及胸腺切除术疗效的相关性]
Kyobu Geka. 1995 Jun;48(6):447-51.
3
Prognosis of thymectomy in myasthenia gravis patients with thymus hyperplasia.重症肌无力伴胸腺增生患者胸腺切除术后的预后
Int J Neurosci. 2017 Sep;127(9):785-789. doi: 10.1080/00207454.2016.1257993. Epub 2016 Nov 23.
4
Thymectomy in late-onset myasthenia gravis.迟发性重症肌无力的胸腺切除术
Arch Neurol. 1982 Feb;39(2):82-3. doi: 10.1001/archneur.1982.00510140016004.
5
Active ectopic thymus predicts poor outcome after thymectomy in class III myasthenia gravis.III 型重症肌无力患者胸腺切除术后出现活动性异位胸腺预示预后不良。
J Thorac Cardiovasc Surg. 2012 Mar;143(3):601-6. doi: 10.1016/j.jtcvs.2011.04.050. Epub 2011 Dec 17.
6
Thymectomy in myasthenia gravis. The Jamaican experience.重症肌无力的胸腺切除术。牙买加的经验。
West Indian Med J. 1992 Jun;41(2):64-7.
7
Experience of thymectomy by median sternotomy in patients with myasthenia gravis.重症肌无力患者经正中胸骨切开术行胸腺切除术的经验
J Pak Med Assoc. 2010 May;60(5):368-70.
8
Maximal thymectomy for myasthenia gravis.重症肌无力的最大程度胸腺切除术
Eur J Cardiothorac Surg. 1995;9(8):461-4. doi: 10.1016/s1010-7940(05)80083-1.
9
Myasthenia gravis, thymectomy, and antiacetycholine receptor antibody.重症肌无力、胸腺切除术和抗乙酰胆碱受体抗体
J Neurol. 1980;224(1):9-15. doi: 10.1007/BF00313202.
10
Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients.胸腺切除术的反应:血清阴性和血清阳性重症肌无力患者的临床和病理特征
Acta Neurol Scand. 2004 Mar;109(3):217-21. doi: 10.1034/j.1600-0404.2003.00209.x.

引用本文的文献

1
Prevalence and risk factors of myasthenia gravis recurrence post-thymectomy.胸腺瘤切除术后重症肌无力复发的患病率和危险因素。
Neurosciences (Riyadh). 2021 Jan;26(1):4-14. doi: 10.17712/nsj.2021.1.20190041.
2
Robotic thoracic surgery: The state of the art.机器人辅助胸外科手术:当前技术水平。
J Minim Access Surg. 2015 Jan-Mar;11(1):60-7. doi: 10.4103/0972-9941.147693.
3
[Application of the da Vinci robotic system in thoracic surgery].[达芬奇机器人系统在胸外科手术中的应用]
Chirurg. 2013 Aug;84(8):643-50. doi: 10.1007/s00104-013-2502-3.
4
Factors predicting surgical outcome of thymectomy in myasthenia gravis: A 16-year experience.重症肌无力胸腺切除手术结果的预测因素:16年经验
Ann Indian Acad Neurol. 2011 Oct;14(4):267-71. doi: 10.4103/0972-2327.91945.
5
Long-term outcome and quality of life after open and thoracoscopic thymectomy for myasthenia gravis: analysis of 131 patients.开胸与胸腔镜下胸腺切除术治疗重症肌无力的长期疗效及生活质量:131例患者分析
Surg Endosc. 2008 Nov;22(11):2470-7. doi: 10.1007/s00464-008-9794-2. Epub 2008 Feb 23.
6
Myasthenia gravis.重症肌无力
Orphanet J Rare Dis. 2007 Nov 6;2:44. doi: 10.1186/1750-1172-2-44.
7
Autoimmune Myasthenia Gravis: Recommendations for Treatment and Immunologic Modulation.自身免疫性重症肌无力:治疗与免疫调节建议
Curr Treat Options Neurol. 2005 Jan;7(1):3-14. doi: 10.1007/s11940-005-0001-7.
8
Results of transcervical thymectomy for myasthenia gravis in 100 consecutive patients.100例连续性重症肌无力患者经颈胸腺切除术的结果。
Ann Surg. 1999 Oct;230(4):555-9; discussion 559-61. doi: 10.1097/00000658-199910000-00011.
9
Thymectomy for myasthenia gravis.重症肌无力的胸腺切除术
Postgrad Med J. 1998 Mar;74(869):139-44. doi: 10.1136/pgmj.74.869.139.
10
Thymectomy in black children with juvenile myasthenia gravis.黑人儿童重症肌无力患者的胸腺切除术
Pediatr Surg Int. 1997 Feb;12(2-3):113-5.